Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40052330/
The clinically important link between LDL cholesterol (LDL - C) lowering and cardiovascular (CV) risk reduction is well-established and reflected in the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines...
Expert consensus highlights LDL-C goal gaps in practice, recommending upfront combination lipid-lowering therapy, including novel agents like bempedoic acid, for high/very high cardiovascular risk and statin-intolerant patients.
Share
I make sure their lipids are tested and ldl at goal. Many cardiologists expect the pcp to manage ongoing risk factors. Now that psk9 inhibitors are better covered I do add on this therapy to maximum statin and ezetimide if not at goal.
Share
richard moro many options to get ldl under 55 to prevent recurrence ot intial vascular disease
Share
ricahard moro there are many options to get ldl to less than 55 in vascular reoccurrence;statins,pck 9 inhibitors benzoic acid to lower cholesterol
Share
pt with stroles,cva stents and MI's try to maintain ldl chholesterol 55 and ubder with statins,pck9 inhibitors with zetia if needed,also benzoic acid to lower options are available
Share